Copyright Reports & Markets. All rights reserved.

Global Toxoplasma Gondii Recombinant Antigen Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Toxoplasma Gondii Recombinant Antigen by Type
    • 1.3.1 Overview: Global Toxoplasma Gondii Recombinant Antigen Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Toxoplasma Gondii Recombinant Antigen Consumption Value Market Share by Type in 2025
    • 1.3.3 Full-Length Antigen
    • 1.3.4 Truncated Antigen
  • 1.4 Global Toxoplasma Gondii Recombinant Antigen Market by Application
    • 1.4.1 Overview: Global Toxoplasma Gondii Recombinant Antigen Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 In Vitro Diagnostics
    • 1.4.3 Vaccine Development
    • 1.4.4 Others
  • 1.5 Global Toxoplasma Gondii Recombinant Antigen Market Size & Forecast
  • 1.6 Global Toxoplasma Gondii Recombinant Antigen Market Size and Forecast by Region
    • 1.6.1 Global Toxoplasma Gondii Recombinant Antigen Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Toxoplasma Gondii Recombinant Antigen Market Size by Region, (2021-2032)
    • 1.6.3 North America Toxoplasma Gondii Recombinant Antigen Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Toxoplasma Gondii Recombinant Antigen Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size and Prospect (2021-2032)
    • 1.6.6 South America Toxoplasma Gondii Recombinant Antigen Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Rekom Biotech
    • 2.1.1 Rekom Biotech Details
    • 2.1.2 Rekom Biotech Major Business
    • 2.1.3 Rekom Biotech Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.1.4 Rekom Biotech Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Rekom Biotech Recent Developments and Future Plans
  • 2.2 Roche
    • 2.2.1 Roche Details
    • 2.2.2 Roche Major Business
    • 2.2.3 Roche Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.2.4 Roche Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Roche Recent Developments and Future Plans
  • 2.3 Thermal Fisher
    • 2.3.1 Thermal Fisher Details
    • 2.3.2 Thermal Fisher Major Business
    • 2.3.3 Thermal Fisher Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.3.4 Thermal Fisher Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Thermal Fisher Recent Developments and Future Plans
  • 2.4 Bio-Rad
    • 2.4.1 Bio-Rad Details
    • 2.4.2 Bio-Rad Major Business
    • 2.4.3 Bio-Rad Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.4.4 Bio-Rad Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bio-Rad Recent Developments and Future Plans
  • 2.5 Abcam
    • 2.5.1 Abcam Details
    • 2.5.2 Abcam Major Business
    • 2.5.3 Abcam Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.5.4 Abcam Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Abcam Recent Developments and Future Plans
  • 2.6 Meridian Bioscience
    • 2.6.1 Meridian Bioscience Details
    • 2.6.2 Meridian Bioscience Major Business
    • 2.6.3 Meridian Bioscience Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.6.4 Meridian Bioscience Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Meridian Bioscience Recent Developments and Future Plans
  • 2.7 Fapon Biotech
    • 2.7.1 Fapon Biotech Details
    • 2.7.2 Fapon Biotech Major Business
    • 2.7.3 Fapon Biotech Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.7.4 Fapon Biotech Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Fapon Biotech Recent Developments and Future Plans
  • 2.8 ViroGen Corporation
    • 2.8.1 ViroGen Corporation Details
    • 2.8.2 ViroGen Corporation Major Business
    • 2.8.3 ViroGen Corporation Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.8.4 ViroGen Corporation Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 ViroGen Corporation Recent Developments and Future Plans
  • 2.9 Medix Biochemica
    • 2.9.1 Medix Biochemica Details
    • 2.9.2 Medix Biochemica Major Business
    • 2.9.3 Medix Biochemica Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.9.4 Medix Biochemica Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Medix Biochemica Recent Developments and Future Plans
  • 2.10 Creative Diagnostics
    • 2.10.1 Creative Diagnostics Details
    • 2.10.2 Creative Diagnostics Major Business
    • 2.10.3 Creative Diagnostics Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.10.4 Creative Diagnostics Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Creative Diagnostics Recent Developments and Future Plans
  • 2.11 Prospec
    • 2.11.1 Prospec Details
    • 2.11.2 Prospec Major Business
    • 2.11.3 Prospec Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.11.4 Prospec Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Prospec Recent Developments and Future Plans
  • 2.12 Cusabio
    • 2.12.1 Cusabio Details
    • 2.12.2 Cusabio Major Business
    • 2.12.3 Cusabio Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.12.4 Cusabio Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Cusabio Recent Developments and Future Plans
  • 2.13 Abbexa
    • 2.13.1 Abbexa Details
    • 2.13.2 Abbexa Major Business
    • 2.13.3 Abbexa Toxoplasma Gondii Recombinant Antigen Product and Solutions
    • 2.13.4 Abbexa Toxoplasma Gondii Recombinant Antigen Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Abbexa Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Toxoplasma Gondii Recombinant Antigen Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Toxoplasma Gondii Recombinant Antigen by Company Revenue
    • 3.2.2 Top 3 Toxoplasma Gondii Recombinant Antigen Players Market Share in 2025
    • 3.2.3 Top 6 Toxoplasma Gondii Recombinant Antigen Players Market Share in 2025
  • 3.3 Toxoplasma Gondii Recombinant Antigen Market: Overall Company Footprint Analysis
    • 3.3.1 Toxoplasma Gondii Recombinant Antigen Market: Region Footprint
    • 3.3.2 Toxoplasma Gondii Recombinant Antigen Market: Company Product Type Footprint
    • 3.3.3 Toxoplasma Gondii Recombinant Antigen Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Toxoplasma Gondii Recombinant Antigen Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Toxoplasma Gondii Recombinant Antigen Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Toxoplasma Gondii Recombinant Antigen Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Toxoplasma Gondii Recombinant Antigen Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Toxoplasma Gondii Recombinant Antigen Consumption Value by Type (2021-2032)
  • 6.2 North America Toxoplasma Gondii Recombinant Antigen Market Size by Application (2021-2032)
  • 6.3 North America Toxoplasma Gondii Recombinant Antigen Market Size by Country
    • 6.3.1 North America Toxoplasma Gondii Recombinant Antigen Consumption Value by Country (2021-2032)
    • 6.3.2 United States Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Toxoplasma Gondii Recombinant Antigen Consumption Value by Type (2021-2032)
  • 7.2 Europe Toxoplasma Gondii Recombinant Antigen Consumption Value by Application (2021-2032)
  • 7.3 Europe Toxoplasma Gondii Recombinant Antigen Market Size by Country
    • 7.3.1 Europe Toxoplasma Gondii Recombinant Antigen Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 7.3.3 France Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Market Size by Region
    • 8.3.1 Asia-Pacific Toxoplasma Gondii Recombinant Antigen Consumption Value by Region (2021-2032)
    • 8.3.2 China Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 8.3.5 India Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Toxoplasma Gondii Recombinant Antigen Consumption Value by Type (2021-2032)
  • 9.2 South America Toxoplasma Gondii Recombinant Antigen Consumption Value by Application (2021-2032)
  • 9.3 South America Toxoplasma Gondii Recombinant Antigen Market Size by Country
    • 9.3.1 South America Toxoplasma Gondii Recombinant Antigen Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Market Size by Country
    • 10.3.1 Middle East & Africa Toxoplasma Gondii Recombinant Antigen Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Toxoplasma Gondii Recombinant Antigen Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Toxoplasma Gondii Recombinant Antigen Market Drivers
  • 11.2 Toxoplasma Gondii Recombinant Antigen Market Restraints
  • 11.3 Toxoplasma Gondii Recombinant Antigen Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Toxoplasma Gondii Recombinant Antigen Industry Chain
  • 12.2 Toxoplasma Gondii Recombinant Antigen Upstream Analysis
  • 12.3 Toxoplasma Gondii Recombinant Antigen Midstream Analysis
  • 12.4 Toxoplasma Gondii Recombinant Antigen Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Toxoplasma Gondii Recombinant Antigen market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Toxoplasma Gondii Recombinant Antigen is a protein produced by genetic engineering technology that mimics the natural antigen of Toxoplasma gondii. Toxoplasma gondii is a parasite that causes toxoplasmosis in humans and animals. Recombinant antigens are used in in vitro diagnostic reagents to detect immune responses caused by Toxoplasma infection, such as the presence of antibodies. By using recombinant antigens, the specificity and sensitivity of diagnosis can be improved and cross-reactions and non-specific reactions can be reduced.
    This report is a detailed and comprehensive analysis for global Toxoplasma Gondii Recombinant Antigen market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Toxoplasma Gondii Recombinant Antigen market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Toxoplasma Gondii Recombinant Antigen market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Toxoplasma Gondii Recombinant Antigen market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Toxoplasma Gondii Recombinant Antigen market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Toxoplasma Gondii Recombinant Antigen
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Toxoplasma Gondii Recombinant Antigen market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Rekom Biotech, Roche, Thermal Fisher, Bio-Rad, Abcam, Meridian Bioscience, Fapon Biotech, ViroGen Corporation, Medix Biochemica, Creative Diagnostics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Toxoplasma Gondii Recombinant Antigen market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Full-Length Antigen
    Truncated Antigen
    Market segment by Application
    In Vitro Diagnostics
    Vaccine Development
    Others
    Market segment by players, this report covers
    Rekom Biotech
    Roche
    Thermal Fisher
    Bio-Rad
    Abcam
    Meridian Bioscience
    Fapon Biotech
    ViroGen Corporation
    Medix Biochemica
    Creative Diagnostics
    Prospec
    Cusabio
    Abbexa
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Toxoplasma Gondii Recombinant Antigen product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Toxoplasma Gondii Recombinant Antigen, with revenue, gross margin, and global market share of Toxoplasma Gondii Recombinant Antigen from 2021 to 2026.
    Chapter 3, the Toxoplasma Gondii Recombinant Antigen competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Toxoplasma Gondii Recombinant Antigen market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Toxoplasma Gondii Recombinant Antigen.
    Chapter 13, to describe Toxoplasma Gondii Recombinant Antigen research findings and conclusion.

    Buy now